Want to see WILYY full AI Analyst Report?
WILYY Stock Chart & Stats
$21.24
$0.00(0.00%)
At close: 4:00 PM EDT
$21.24
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$13.80 - $23.04
Previous CloseN/A
Volume30.00
Average Volume (3M)4.00
Market Cap
$9.15B
Enterprise Value$11.45K
Total Cash (Recent Filing)$1.50B
Total Debt (Recent Filing)$20.28B
Price to Earnings (P/E)37.2
Beta0.89
Next Earnings
Feb 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.73
Shares Outstanding423,506,600
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)4.48
Price to Sales (P/S)1.92
P/FCF Ratio13.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Organic Growth And Upgraded OutlookStrong organic expansion and upgraded guidance indicate sustained demand for Demant's hearing healthcare products and services. This supports revenue visibility over the next several months, while acquisitive growth broadens the platform and distribution reach.
Premium Product Innovation And Gross MarginPremium product momentum, higher average selling prices and differentiated AI-enabled features can reinforce Demant's competitive position. The combination supports pricing power and the strong gross-margin profile needed to absorb ongoing investment.
Cash Generation And Efficiency ProgramPositive operating cash generation provides funding for product development, integration and debt reduction. The increased savings target could improve underlying earnings durability, particularly if execution offsets inflation, launch spending and integration costs.
Bears Say
Elevated Leverage And Refinancing RiskThe more debt-heavy capital structure reduces financial flexibility and raises refinancing sensitivity if earnings weaken. Although leverage has improved from the acquisition spike, management still expects net leverage above its 2.0-2.5 target range.
Operating And Net Margin CompressionThe decline in operating and net profitability suggests that costs, mix or one-off charges are absorbing part of the strong top-line growth. Sustained margin pressure would limit earnings conversion and weaken the benefit of future revenue expansion.
Integration, Regional And Competitive HeadwindsHigher integration and restructuring costs can delay realization of acquisition synergies and savings. Regional demand weakness and a crowded product-launch cycle add longer-lasting execution, pricing and market-share risks beyond normal quarterly volatility.
Demant News
WILYY FAQ
What was Demant’s price range in the past 12 months?
Demant lowest stock price was $13.80 and its highest was $23.04 in the past 12 months.
What is Demant’s market cap?
Demant’s market cap is $9.15B.
When is Demant’s upcoming earnings report date?
Demant’s upcoming earnings report date is Feb 09, 2027 which is in 171 days.
How were Demant’s earnings last quarter?
Demant released its earnings results on Aug 11, 2026. The company reported $0.443 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Demant overvalued?
According to Wall Street analysts Demant’s price is currently Overvalued.
Does Demant pay dividends?
Demant does not currently pay dividends.
What is Demant’s EPS estimate?
Demant’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Demant have?
Demant has 423,506,600 shares outstanding.
What happened to Demant’s price movement after its last earnings report?
Demant reported an EPS of $0.443 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.523%.
Which hedge fund is a major shareholder of Demant?
Currently, no hedge funds are holding shares in WILYY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Demant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.36%
Trailing 12-Months
Company Description
Demant
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
WILYY Company Deck
WILYY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong operational and financial positives: robust reported revenue growth (15%), gross profit expansion (+17%) and gross margin improvement (+1.1 ppt), solid cash generation, successful commercial momentum driven by Oticon Zeal and the new Oticon Reveal product positioning, and upgraded full-year guidance. Offsetting these positives are elevated and increased special items tied to acquisitions and restructurings, FX headwinds, regional softness (notably China and managed care in the U.S.), and the risk of competitive launches in H2. On balance, the company’s financial performance, product momentum, successful integration progress and strengthened outlook outweigh the headwinds and one-off costs.View all WILYY earnings summariesTechnical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―